A Phase 1 interventional study of BI 10773 and BI 10773 in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 2 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-14.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 90th largest by enrollment, is one of 4 that started in 2009, is one of 24 in phase 1, and was the 29th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 86th largest by enrollment of the 96 interventional ones that give a count, is one of 9 that started in 2009, is one of 19 in phase 1, and was the 75th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation. Co medication known to inhibit or induce P-glycoprotein or is not allowed. Inhibitors of P-glycoprotein or CYP3A (cytochrom P3A) are e.g.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Dose Administration (type 2 diabetes and mild renal impairment)
Drug: BI 10773
Single Dose Administration (type 2 diabetes and moderate renal impairment)
Drug: BI 10773
Single Dose Administration (severe renal impairment 8)
Drug: BI 10773
Single Dose Administration (kidney failure)
Drug: BI 10773
Single Dose Administration (type 2 diabetes and normal renal function)
Drug: BI 10773
AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)
Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
Time frame: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Cmax (Maximum Concentration of the Analyte in Plasma)
Maximum concentration of Empagliflozin in plasma
Time frame: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Time to Maximum Concentration of the Analyte in Plasma
Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)
Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Half-life and Mean Residence Time of the Analyte in Plasma
Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body
Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Terminal Rate Constant in Plasma
Terminal rate constant in plasma (Lz)
Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Apparent Clearance of the Analyte in the Plasma After Extravascular Administration
Apparent clearance of the analyte in the plasma after extravascular administration
Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Apparent Volume of Distribution During the Terminal Phase Lz
Apparent volume of distribution during the terminal phase Lz
Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)
Amount of analyte that is eliminated in urine over the time interval 0-96 hours.
Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)
Fraction of analyte excreted unchanged in urine from time point 0-96 hours.
Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
Renal Clearance of the Analyte in Plasma After Extravascular Administration
Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.
Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)
Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity
Time frame: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Plasma Protein Binding
Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation.
Time frame: 1 h before drug administration and 1:30 and 3:00 h after drug administration
Total Urinary Glucose Excretion (UGE)
Change from baseline in total urinary glucose excretion
Time frame: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)
Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements
Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements
Time frame: Drug administration until end-of-study-examination, 5 days
Assessment of Tolerability by Investigator
Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.
Time frame: Drug administration until end-of-study-examination, 5 days
The trial was conducted in two trial centres as an open-label, parallel group design with one treatment period. The trial was performed in 40 male and female patients who were assigned to five treatment groups according to their creatinine clearance.
| Milestone | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Started | 8 | 9 | 7 | 8 | 8 |
| Completed | 8 | 9 | 7 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
| nmol*h/L | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity) | 10500 ± 17.6 | 12400 ± 21.6 | 12600 ± 27.1 | 17500 ± 18.9 | 15600 ± 38.6 |
Maximum concentration of Empagliflozin in plasma
| nmol/L | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Cmax (Maximum Concentration of the Analyte in Plasma) | 1210 ± 24.1 | 1430 ± 33.1 | 1230 ± 30.9 | 1450 ± 33.0 | 1250 ± 25.9 |
Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)
| h | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Time to Maximum Concentration of the Analyte in Plasma | 1.00 (1.00 to 3.00) | 2.50 (2.00 to 4.00) | 2.00 (1.50 to 3.00) | 2.00 (0.67 to 4.00) | 2.50 (1.50 to 3.00) |
Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body
| h | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Terminal half-life | 17.4 ± 57.4 | 19.3 ± 81.6 | 19.5 ± 63.9 | 22.5 ± 74.3 | 18.5 ± 62.6 |
| Mean residence time | 13.1 ± 37.4 | 15.7 ± 44.6 | 18.4 ± 52.7 | 22.2 ± 57.6 | 19.8 ± 51.2 |
Terminal rate constant in plasma (Lz)
| 1/h | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Terminal Rate Constant in Plasma | 0.0398 ± 57.4 | 0.0360 ± 81.6 | 0.0355 ± 63.9 | 0.0308 ± 74.3 | 0.0375 ± 62.6 |
Apparent clearance of the analyte in the plasma after extravascular administration
| mL/min | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Apparent Clearance of the Analyte in the Plasma After Extravascular Administration | 176 ± 17.6 | 149 ± 21.6 | 147 ± 27.1 | 106 ± 18.9 | 119 ± 38.6 |
Apparent volume of distribution during the terminal phase Lz
| L | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Apparent Volume of Distribution During the Terminal Phase Lz | 266 ± 55.1 | 248 ± 76.3 | 248 ± 55.5 | 206 ± 78.0 | 190 ± 45.1 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
| nmol*h/L | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) | 10300 ± 17.5 | 12100 ± 20.9 | 12100 ± 24.4 | 16500 ± 19.9 | 14900 ± 34.4 |
Amount of analyte that is eliminated in urine over the time interval 0-96 hours.
| nmol | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h) | 17300 ± 26.1 | 12100 ± 43.8 | 6840 ± 85.5 | 3730 ± 49.3 | 300 ± 117 |
Fraction of analyte excreted unchanged in urine from time point 0-96 hours.
| percentage of analyte | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours) | 15.6 ± 26.1 | 10.9 ± 43.8 | 6.16 ± 85.5 | 3.36 ± 49.3 | 0.271 ± 117 |
Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.
| mL/min | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Renal Clearance of the Analyte in Plasma After Extravascular Administration | 28.0 ± 19.5 | 16.7 ± 53.7 | 9.39 ± 87.9 | 3.70 ± 38.5 | 0.349 ± 188 |
Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity
| percent | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| %AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity) | 0.869 ± 225 | 1.07 ± 243 | 1.21 ± 223 | 1.78 ± 334 | 1.14 ± 330 |
Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation.
| percentage of plasma protein binding | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Pre-dose | 83.61 ± 1.10 | 82.72 ± 3.36 | 81.29 ± 2.48 | 79.98 ± 2.42 | 81.08 ± 1.54 |
| 1:30 h after dosing | 85.18 ± 1.91 | 83.70 ± 2.49 | 82.68 ± 2.76 | 81.02 ± 1.73 | 81.09 ± 1.94 |
| 3:00 h after dosing | 83.94 ± 1.88 | 83.18 ± 2.58 | 81.90 ± 1.69 | 80.38 ± 1.61 | 80.32 ± 2.00 |
Change from baseline in total urinary glucose excretion
| mg | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Total Urinary Glucose Excretion (UGE) | 97643 ± 7204 | 61590 ± 6892 | 55674 ± 16891 | 18251 ± 3925 | 779 ± 904 |
Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements
| participants | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Physical examination | 0 | 0 | 0 | 0 | 0 |
| Vital signs | 0 | 0 | 0 | 0 | 0 |
| ECG | 0 | 0 | 0 | 0 | 0 |
| Laboratory Measurements | 0 | 0 | 0 | 0 | 0 |
Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.
| participants | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| Good | 8 | 9 | 7 | 8 | 8 |
| Satisfactory | 0 | 0 | 0 | 0 | 0 |
| Not satisfactory | 0 | 0 | 0 | 0 | 0 |
| Bad | 0 | 0 | 0 | 0 | 0 |
| Not assessable | 0 | 0 | 0 | 0 | 0 |
Collected over From drug administration until end of trial examination, 5 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Renal Function | — | 0/8 (0%) | 1/8 (12.5%) |
| Mild Renal Impairment | — | 0/9 (0%) | 0/9 (0%) |
| Moderate Renal Impairment | — | 0/7 (0%) | 1/7 (14.3%) |
| Severe Renal Impairment | — | 0/8 (0%) | 0/8 (0%) |
| Kidney Failure | — | 0/8 (0%) | 2/8 (25%) |
| Event | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure |
|---|---|---|---|---|---|
| ErythemaMetabolism and nutrition disorders | 0/8 | 0/9 | 1/7 | 0/8 | 0/8 |
| PruritusSkin and subcutaneous tissue disorders | 0/8 | 0/9 | 1/7 | 0/8 | 1/8 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/9 | 0/7 | 0/8 | 1/8 |
| NauseaGastrointestinal disorders | 1/8 | 0/9 | 0/7 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 1/8 | 0/9 | 0/7 | 0/8 | 0/8 |
The treated set included all patients who were dispensed study medication and were documented to have at least one dose of investigational treatment.
| Age, Continuous(years) | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure | Total |
|---|---|---|---|---|---|---|
| Mean | 54.5 ± 11.7 | 60.0 ± 8.8 | 63.1 ± 9.5 | 56.0 ± 12.9 | 45.8 ± 12.0 | 55.8 ± 12.0 |
| Sex: Female, Male(Participants) | Normal Renal Function | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | Kidney Failure | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 6 | 3 | 1 | 4 | 21 |
| Male | 1 | 3 | 4 | 7 | 4 | 19 |
The record gives a start of Jul 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin